# Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines

> **NCT05668065** · PHASE3 · COMPLETED · sponsor: **Institut Pasteur de Tunis** · enrollment: 199 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** CoronaVac/CoronaVac
- **BIOLOGICAL:** CoronaVac/BNT162b2

## Key facts

- **NCT ID:** NCT05668065
- **Lead sponsor:** Institut Pasteur de Tunis
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-22
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-06-25
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2023-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05668065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05668065, "Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05668065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*